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Resumo 
 
 
 
Enfarte agudo do miocádio (AMI), sepsis e artrite reumatóide (AR) são três doenças distintas que 
têm como factor comum serem doenças inflamatórias. São responsáveis por milhões de mortes por 
ano em todo o mundo e têm, também, grande peso económico nos recursos hospitalares. Apesar de o 
conhecimento acerca dos mecanismos destas doenças aumentar de ano para ano, existem ainda muitas 
lacunas por preencher. A existência de biomarcadores que permitam diagnosticar preventivamente a 
doença bem como prever desfechos mais desfavoráveis são algumas destas lacunas. Este estudo foi 
realizado com a intenção de estudar a evolução de quatro marcadores hemorreológicos 
(deformabilidade eritrocitária, agregação eritrocitária, monóxido de azoto – NO e S-nitrosoglutatuão – 
GSNO) de modo a compreender o seu mecanismo e as diferenças existentes nos três diversos tipos de 
doenças inflamatórias. O estudo incidiu sobre quatro grupos: sepsis (14 doentes), AR (25 doentes), 
enfarte agudo do miocárdio (STEMI; 15 doentes) e controlo (CTR; 15 voluntários saudáveis). No 
grupo STEMI foram feitas duas medições, correspondendo a primeira à admissão no Serviço de 
Urgência e a segunda um mês depois. No grupo da sepsis quatro medições foram feitas a cada doente - 
admissão na Unidade de Cuidados Intensivos (UCI), 24 horas, 72 horas depois e alta da UCI. 
Observou-se uma diferença significativa dos níveis de agregação eritrocitária para 10s entre os grupos 
STEMI admissão e controlo. Diferenças significativas de deformabilidade, agregação e GSNO foram 
observadas entre os grupos sepsis (em qualquer ponto de recolha) e CTR. Para além disto, 
verificaram-se também variações longitudinais significativas no grupo sepsis para as concentrações 
eritrocitárias de GSNO. Em conclusão, verificaram-se valores anormais de alguns dos parâmetros 
hemorreológicos estudados nas doenças inflamatórias estudadas, ou seja, sepsis, AMI e AR. Tais 
resultados parecem apontar para uma relação entre o processo inflamatório a as alterações 
hemorreológicas no sangue.  
 
 
 
Termos-chave: inflamação, eritrócitos, monóxido de azoto, hemorreologia. 
  
 
  
 
vii 
 
Abstract 
 
 
 
Acute myocardial infarction (AMI), sepsis and rheumatoid arthritis (RA) are part of the 
inflammatory diseases’ group. Every year millions of people are affected and die because of them, all 
around the globe. In the past years our knowledge of these diseases has increased and a light on their 
pathophysiology has been shed, but there is still much more to be discovered. Biological markers that 
would make pre-disease diagnosis possible would change many of the outcomes for patients suffering 
from them. The aim of this study was to access the evolution of four hemorheological markers 
(erythrocyte deformability, erythrocyte aggregation, nitric oxide – NO and S-nitrosoglutathione – 
GSNO) in order to understand their behaviour in three types of inflammatory diseases. Four study 
groups were created: ST-elevation myocardial infarction (STEMI) group (15 patients), RA (25 
patients), sepsis (14 patients) and the control group (CTR; 15 healthy volunteers). In STEMI group 
two different measurements were taken, one at time of hospital admission and the other after a month. 
In the sepsis group four measurements were taken throughout the internment in the Intensive Care 
Unit (ICU): admission, 24 hours, 72 hours after and discharge. Significant difference was observed in 
the 10s erythrocyte aggregation marker between the STEMI patients at hospital admission and CTR 
group. Significant differences of deformability, aggregation and GSNO were obtained upon 
comparison of sepsis patients (at all time-points) and CTR. In addition to this, the longitudinal changes 
of GSNO erythrocyte concentrations were significant. In conclusion, abnormal values for some of the 
studied hemorheological parameters were verified in inflammatory diseases, namely myocardial 
infarction (STEMI), sepsis and rheumatoid arthritis. The results seem to point out to a relation 
between inflammation and the hemorheological alterations. 
 
 
 
Keywords: inflammation, erythrocytes, nitric oxide, hemorheology. 
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1. – Introduction 
 
1.1. – General Introduction 
 
Inflammation is a biological mechanism that occurs as a normal response of our body to infections 
and injuries. When this process becomes excessive it brings a great deal of harm. 
There is a large number of diseases that occur as a consequence to uncontrolled inflammation: 
necrotizing enterocolitis, acne, angina, pharyngitis, pyelitis, pleurisy, empyema, pelvic inflammation 
disease, gastroenteritis, urinary tract infection, and many others. They target different organs and have 
different outcomes, but they all have the same inflammatory agents: inflammatory cytokines, 
arachidonic acid-derived eicosanoids such as prostaglandins, thromboxanes and leukotrienes, adhesion 
molecules and other agents that can have a role in inflammation such as reactive oxygen species 
(Philip, 2006). 
In this study three different inflammatory diseases are going to be approached - acute myocardial 
infarction, sepsis and rheumatoid arthritis - and compared in terms of hemorheological markers. 
Hemorheology is the science of the physical properties of blood flow and deformation behaviour 
in the circulatory system.  
In this study four hemorheological markers – erythrocyte aggregation, erythrocyte deformability, 
erythrocyte nitric oxide (NO) and S-nitrosoglutathione (GSNO) concentrations - are going to be 
studied in order to observe their behaviour and their differences among three inflammatory conditions, 
and also in healthy people. 
1.2. – Inflammatory Diseases 
1.2.1. – Acute Myocardial Infarction 
Cardiovascular disease (CVD) is the main cause of death globally. In 2008, roughly 17.3 million 
people died from CVDs, which accounts for 30% of all global deaths that year (WHO, 2011). 
According to the World Health Organization, is it projected to remain the single leading cause of death 
across the globe. Therefore, an understanding of their pathophysiology is crucial and the need for 
 
markers that could uncover the presence and imminence of the disease, as well as for efficient 
therapeutic agents, is urgent. 
ST-segment elevation myocardial infarction (STEMI) is a specific type of acute myocardial 
infarction (AMI), and part of the cardiovascular diseases group. In this condition the coronary artery is 
completely blocked, and as a result all the heart muscle that is being supplied by the affected artery is 
in ischemia and can start to die depending on the duration of the ischemia. This type of myocardial 
infarction is detected on an electrocardiogram, as it produces an elevation in the ST segment, which 
means that an elevated amount of heart muscle is being damaged. It is an acute event that results from 
thrombosis developing on a coronary atherosclerotic plaque (Libby, 2001), as a consequence of its 
disruption (Libby, 2006). 
The current view of atherosclerosis as a lipid storage disease has been completely substituted by 
the notion that it is indeed an inflammatory disease (Fig. 1.1), with extensive evidences and studies 
backing up this fact. Several other concepts have also changed during the last years: arteries are not 
viewed as inanimate conduits but as highly organized organs composed by living cells, and evidences 
suggest that atheromatous plaques develop within the arterial wall, instead of on it. We now realize 
that atherosclerosis is not a direct component of aging, and that our lifestyle and behaviour can modify 
the inflammatory processes that lead to the disease (Libby, 2006). Furthermore, it is believed that the 
occurrence of an acute coronary event is not related to the degree of stenosis nor do the lesions occur 
randomly, but instead is dependent of the physical properties of the plaque and its vulnerability. 
Vulnerable plaques are the ones who suffer plaque disruption. These are plaques whose structure and 
content makes them likely to undergo thrombosis in the future. Those features are: a large lipid core 
occupying at least 50% overall plaque volume, a high density of macrophages, a low density of 
smooth muscle cells in the capsule, a high tissue factor content and a thin plaque cap with 
disorganized collagen structure (Davies, 2000). 
As referred above, disruption of an atherosclerotic plaque is the main cause of AMI. The occlusion 
reduces the blood flow of that fraction of the myocardium, which results in progressive tissue 
ischemia. Necrosis begins after approximately 30 minutes. If the perfusion of the myocardium stays 
for about 3 hours, profound ischemia, necrosis and acute episode of infarction occur (Collinson and 
Gaze, 2007). Cell death during STEMI is permanent and so the need to restore tissue perfusion is 
urgent. Necrosis induces generation of free radicals. They trigger a cytokine cascade initiated by the 
release of tumour necrosis factor-alpha (TNF-α) that results in an inflammatory response. Neutrophils 
are recruited to the ischemic tissue and infiltrate the endothelium, further contributing to the persistent 
inflammatory response (Frangogiannis et al., 2002). After infarction the repair and remodelling stage 
begins, characterized by structural rearrangement of the cardiac chamber wall. Proliferation of 
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interstitial fibroblasts along with deposition of extracellular matrix components leads to myocardial 
stiffness and diastolic dysfunction that could ultimately result in heart failure (Kapoun et al., 2004). 
 
Figure 1.1 - Development of atherosclerosis. The progression of the atherosclerotic lesion from normal vessel up 
until the atherosclerotic plaque is formed (Adapted from Wall, 2012). 
 
1.2.2. – Sepsis 
Sepsis is another disease that is a leading cause of death (Xu et al., 2010). Over the years, there 
has been an increase of hospitalizations with sepsis as a primary or secondary diagnosis (Hall et al., 
2011). It is an inflammatory disease that kills more than 6 million infants and young children, and 
100,000 new mothers every year (Hall et al, 2011). 
Sepsis is an inflammatory disease that starts with a bacterial or fungal infection. Paradoxically, it 
is not the infection that kills people but instead is the host immune response while attempting to fight 
it. The infection triggers an overwhelming immune response as the body releases chemicals into the 
blood to fight the infection, which triggers widespread inflammation. The most common cause of 
sepsis are Gram-positive bacterial pathogens but fungal organisms are increasing rapidly (Martin, 
2012). Blood clots appear in several sites of the body and cause diminished blood flow, which in turn 
 
deprives the organs from oxygen and nutrients. It also induces changes in the circulatory system, 
especially in the microcirculation (Hinshaw, 1996). 
There are different levels of sepsis – sepsis, severe sepsis and septic shock. Cases of severe sepsis 
and septic shock are lower than those of sepsis. In severe cases there is acute organ dysfunction and 
possible failure. These cases are related to the source of infection. In septic shock there is a weakening 
of the heart due to a decrease in the blood pressure. 
There have been longitudinal changes in the incidence of sepsis. The numbers of hospitalized 
patients are getting higher each year and cases of sepsis and severe sepsis are increasing in excess of 
the growth of population. In the developing world, sepsis is more common among the younger people 
and the organisms that trigger it are likely to be Gram-negative enteric pathogens and atypical 
pathogens (Martin, 2012). There is a differential risk for developing sepsis regarding to specific 
patient factors. Conditions that alter the immune system increase risk of getting sepsis. Other factors 
are race, ethnicity and gender: males have a higher risk than females, and though the mechanisms 
behind the difference among race and ethnicity are not clear, it is observed that Caucasians have lower 
risk of developing sepsis (Martin, 2012). 
 
1.2.3. – Rheumatoid Arthritis 
According to the World Health Organization, rheumatoid arthritis (RA) is a chronic systemic 
disease that affects the joints, connective tissue, muscle, tendons and fibrous tissue, resulting in an 
accumulation of fluid in the joints and causing pain and systemic inflammation (WHO, 2013). It is a 
complex systemic multifactorial inflammatory process (Scher, 2012) of unknown etiology. First 
coined by Sir Alfred Garrod in 1851 (Scher, 2013) it strikes between the ages of 20 to 40 and turns 
into a chronic disabling condition that causes pain and deformity, and possibly even severe disability. 
The statistic data show that the prevalence varies between 0.3% and 1% and mainly affects the female 
gender and people in developed countries (WHO, 2013). 
Activated macrophages, T lymphocytes and plasma cells infiltrate to the synovium (thin 
membrane present in joints that lines the joint capsule and also secretes synovial fluid) and stimulate 
joint lesions. Biopsies taken from RA patients contain high concentrations of cytokines such as TNF-
α, interleukins (IL)-1β, IL-6 and IL-8 (Philip, 2006). An increase of inflammatory markers is 
antecedent of disease progression and also joint destruction, which occurs in the first years of RA 
(Matsuda et al., 1998). 
The main goals for the treatment of RA are the control of signs and symptoms, prevention of joint 
damage progression and the achievement of remission (Scirè et al, 2009). Cardiovascular disease 
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(such as acute myocardial infarction) is a major source of morbidity and mortality in RA (Solomon et 
al, 2013). It is interesting to note that traditional cardiovascular risk factors do not entirely explain this 
connection. 
 
1.3. – Blood Hemorheology 
The blood is a two-phased liquid formed by 45% formed elements (erythrocytes, leukocytes and 
platelets) and 55% plasma. It carries hormones, enzymes and vitamins, oxygen to tissues, collects 
carbon monoxide, conveys nutritive substances (amino acids, sugars, mineral salts), gathers excreted 
material which is later eliminated through renal filters and participates in the defence of the organism 
by means of phagocytic activity of leukocytes, bactericidal power of serum and immune response of 
lymphocytes (Bianco, 2013). The fluidity of blood at a given shear rate and temperature is determined 
by rheological properties of plasma and formed elements, and by the volume fraction (hematocrit) of 
the formed elements (Baskurt e Meiselman, 2003). 
Erythrocytes (Fig. 1.2), or red blood cells (RBC), are the most numerous blood cells: about 4-6 
millions/mm
3
. They have no nucleus, are rich in hemoglobin and are responsible for providing oxygen 
to tissues. They also play a major role in the process of inflammation. In fact, alterations of their 
hemorheological properties can indicate the presence of inflammation. 
 
 
Figure 1.2 - Red blood cells in two types of vessels. This figure shows the uptake and/or release of nitric oxide 
by RBC in different vessels (Adapted from Gross SS, 2001). 
 
Deformability is one of the properties of the erythrocytes, determined by 3 main factors: 
viscoelastic properties of the membrane (flexibility), viscosity of the content (fluidity of the 
cytoplasm) and geometry (surface/volume globular ratio). It is what determines the average life of the 
erythrocyte and the rheologic properties of the blood, being of extreme importance in the 
microcirculation. It is also crucial in the oxygenation of hemoglobin and tissues. Viscoelastic 
properties of the membrane allow it to deform greatly and recover, if the equilibrium point is not 
surpassed (Silva, 1982). 
Erythrocyte aggregation is one of the factors that determines blood viscosity, along with the 
hematocrit, plasmatic viscosity and erythrocyte deformability (Silva, 1982). It affects directly the RBC 
distribution and the dynamic of the blood flow, especially in microcirculation. Aggregation is 
responsible for the shear thinning behaviour of normal human blood – fluid’s viscosity decreases with 
increasing rate of shear stress due to aggregate’s dispersion (Meiselman et al., 2007). RBCs in humans 
tend to aggregate forming a shape that looks like a stack of coins and is called rouleaux. The 
aggregation becomes enhanced in the presence of acute phase proteins such as fibrinogen and is 
reversible (Baskurt et al., 2009). When examining the blood of healthy donors, aggregates appear to 
have relatively weak attractive forces, as they break up when subjected to relatively low shear rates – 
20-40 s
-1
. The aggregating potential of cells differs with a large variation between all healthy persons, 
and more dense cells exhibit greater aggregation (Meiselman et al., 2007). 
RBC take part in severe coronary occlusion mostly in conditions of low shear rate, e.g. within the 
microcirculation in peri-infarct domain of myocardium (Dormandy et al., 1982). 
Nitric oxide (NO) is an endothelium-derived relatively stable gas with a very broad spectrum of 
actions: dilates blood vessels, reduces platelet and monocyte adhesion, reduces release of superoxide 
radicals, prevents smooth muscle cells proliferation and reduces oxidation of low density lipoprotein 
(LDL). All these effects are directly related to atherosclerosis and show the importance of NO in the 
disease. It is produced by enzymes called the nitric oxide synthases (NOS) while they convert L-
arginine into L-citruline, and after formed it binds the heme group of soluble guanylate cyclase 
(Cooper and Brown, 2008). There are three kinds of NOS: two kinds, (nNOS and eNOS), are 
constitutive forms present in neuronal and endothelial cells that produce basal levels of NO, while the 
third form (iNOS) is an inducible form of the enzyme found in macrophages, monocytes, neutrophils 
and Kupffer cells (El-Sallab et al., 2002). After formed, endothelial NO is released into the vessel 
lumen and can be scavenged by erythrocytes. It diffuses into the erythrocyte through band 3 protein 
and becomes fixed by the haemoglobin molecules (Fig. 1.2), generating nitrosohemoglobin. 
Erythrocytes scavenge NO when oxygen tension is high and liberate it when it is low (Saldanha et al., 
2013). It also has other roles: is a key component of the respiratory cycle, causes smooth muscle 
relaxation, has the ability to diffuse through the cell membrane. It directly affects RBC deformability, 
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so a possibility of NO having a regulatory role on erythrocyte deformability has been proposed (Bor-
Kucukatay et al., 2003). Under normal conditions NO has an anti-inflammatory role, but when there is 
a destabilization in the surrounding environment and in NO it may turn into a pro-inflammatory 
signalling molecule. After diffusing into erythrocytes, NO may be stored or return to the blood stream 
as an active S-nitrosothiol molecule. Nitrites (NO2-) and nitrates (NO3-) are the major stable 
metabolites that result from its oxidation (Kesmarky et al., 1998). 
S-Nitrosoglutathione (GSNO) is an endogenous nitrosothiol with a critical role in NO signalling 
(Fig.1.3). It is produced by the reaction of NO with glutathione (GSH) and is much more stable than 
NO in biological systems. It can act as a nitrosylating agent, which leads to it having anti-
inflammatory effects, and it also presents antioxidant effects through redox modulation, namely down 
regulation of peroxynitrite and up regulation of glutathione. GSNO inhibits platelet activation, 
inflammatory processes in endothelial and T cells, and reduces embolization in humans. A 
GSNO/hemoglobin homeostasis in circulation is required for GSNO to perform its S-nitrosylation 
mechanisms (Khan et al., 2011). 
 
 
Figure 1.3 – Synthesis of GSNO. GSNO pathways along his synthesis (Adapted from Colagid, S-
Nitrosoglutathione, www.wikipedia.org). 
 
1.4. – Aims of This Study 
This work is part of a broad project whose final goal is to contribute to the increase of knowledge 
about the pathophysiology of inflammatory diseases through the analysis and study of several markers 
implied in the origin and progression of these diseases. The present thesis has benefited from ongoing 
collaborations with medical staff from several hospitals. 
The main goal of this study was to investigate the contribution of four hemorheological markers 
for the pathophysiology of inflammation and their evolution, and see if it can be quantified and 
possibly used as part of the diagnosis or even prevention methods. 
 
The process used to reach this aim was analysis of four hemorheological markers: 
erythrocyte deformability 
    erythrocyte aggregation 
    NO 
GSNO 
 
Those markers were measured in the blood of patients that suffered from two different 
inflammatory diseases: 
    acute myocardial infarction 
    sepsis 
 
The results will then be compared with a control group constituted by healthy individuals with no 
sign of inflammation and also with patients suffering from a chronic inflammatory disease (patients 
with rheumatoid arthritis – RA). 
Patients with acute myocardial infarction were monitored at the moment of their hospital 
admission and after 30 days, while sepsis patients were monitored at the time of their admission in the 
intensive care unit (ICU), 24 hour after, 72 hours after and at the time of their discharge. 
This specific study of erythrocytes and their changes during various phases of inflammation may 
help strengthen our knowledge of these diseases and further down the road have a direct impact on the 
clinical procedures in order to achieve a faster, earlier and most effective diagnosis. 
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2. – Longitudinal evaluation of hemorheological markers in 
patients with acute myocardial infarction 
2.1. – Role of STEMI in World’s Health  
AMI is a cardiovascular disease that plays a huge role in the world´s health panorama, as it is the 
main cause of death globally. STEMI is the most dangerous type of AMI as it blocks a great amount 
of hearth muscle, which ends up by being damaged. 
A series of studies that involve thousands of people have been done along the years, and the 
knowledge of this disease and its mechanisms has improved greatly. Despite this, a lot more is still to 
be uncovered in order to let us achieve efficient prevention methods, diagnosis, and treatment. 
STEMI starts with the formation of the atherosclerotic lesion and culminates with thrombosis – 
formation of a blood cloth (thrombus) – that obstructs the vessel and causes ischemia. Thrombosis of 
the plaque occurs by two different processes. The first one is endothelial erosion and occurs because 
of the extension of endothelial denudation, which makes large areas of subendotelial connective tissue 
of the plaque exposed. The probable explanation for this process is macrophage. When highly 
activated, they cause endothelial cell death by apoptosis and production of proteases. Studies linked 
endothelial cell loss and proximity of macrophages. The second process is plaque disruption. In this 
scenario the plaque cap tears and the lipid core is exposed to blood in the arterial lumen and starts to 
coagulate. Coagulation is fast because the lipid core is highly thrombogenic- it has tissue factor, 
fragments of collagen and crystalline surfaces (Davies, 2000). 
Inflammation plays a key role in the mechanism of this disease by promoting several actions: the 
initiation of atherosclerotic lesion, its progression to complex plaque, the weakening of the fibrous cap 
(which renders plaque prone to rupture), and the boosting of thrombogenicity of the lipid core (Davies, 
2000). 
 
2.2. – Objectives 
The aim of this chapter is to unveil the contribution of hemorheological parameters for the STEMI 
pathophysiology and their evolution. To achieve the proposed objective, four hemorheological 
markers – erythrocyte deformability, erythrocyte aggregation, NO and GSNO erythrocyte 
concentrations – were measured in patients with AMI upon their hospital admission and 30 days after. 
 
Furthermore, the results were compared with patients suffering from a chronic inflammatory disease, 
patients with RA, and without inflammation, the control group.  
 
2.3. – Materials & Methods 
2.3.1. – Study Groups 
The study groups were composed by both female and male patients and were organized according 
to the illness these patients presented when admitted to the hospital. 
In this chapter two study groups (myocardial infarction group and rheumatoid arthritis group) are 
going to be analysed and compared. A control group was also created with females older than 50 years 
old and males. The samples were taken from October 2012 to June 2013. 
ST-elevation Acute Myocardial Infarction (STEMI) Group: Composed by 15 patients (5 
females and 10 males) with documented ST-elevation changes, creatine kinase 3 times above normal 
and with primary coronary intervention (PCI) as reperfusion therapy. STEMI patients were enrolled 
during the first 24 hours of hospital admission. Blood samples were taken from patients immediately 
after being admitted into the Serviço de Cardiologia at Hospital de Santa Marta and before the 
administration of IIb/IIIa inhibitors and PCI intervention. Only patients with no previous history of 
heart diseases and who were suffering from myocardial infarction for the first time were accepted into 
this group. A second sample (follow-up) was taken about a month after the episode. 
Rheumatoid Arthritis Group: Composed by 25 patients (19 females and 6 males) from Consulta 
de Reumatologia from Hospital Egas Moniz (CHLO-EPE) without known antecedents of ischemic or 
pulmonary pathology and without electrocardiographic changes or other positive stress tests. Blood 
samples were taken from patients suffering from rheumatoid arthritis during their appointment at 
Hospital de Santa Marta. Patients were previously diagnosed with rheumatoid arthritis and were part 
of an ongoing study at the Hospital. 
Control Group: Composed by 15 healthy volunteers (4 females and 11 males). Inclusion criteria 
for reference controls was absence of any history of cardiovascular diseases, any life threatening 
diseases, or any other disease or condition that would impair compliance. Blood samples were 
obtained by vein puncture from healthy volunteer donors at the Banco Público de Sangue do Instituto 
Português do Sangue (Lisbon) under an institutional agreement with Instituto de Bioquímica da 
Faculdade de Medicina da Universidade de Lisboa. All donors were informed and signed a written 
consent. 
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Blood samples (9 ml) from all subjects enrolled were drawn into heparin tubes and were tested 
within the next 3 hours. 
The medical team of the patients at Hospital de Santa Marta provided all clinical data. 
 
2.3.2. – Methods 
As mentioned previously, in the present study four hemorheological parameters were measured - 
erythrocyte deformability, erythrocyte aggregation, NO and GSNO erythrocyte concentrations. Above 
are described the methodologies used for each determination (the list of materials and reagents used in 
this determination is presented in the Appendix B). 
Erythrocyte Aggregation 
 
Aggregation of erythrocytes in the blood samples was tested using the Myrenne Aggregometer 
MA-1 (Schmid-Schönbein et al., 1983; Rampling and Martin, 1989). The red blood cell aggregates are 
placed in a rotating cone plate chamber and dispersed during 10 s with a shear rate of 600 s
-1
 and after 
stopped. Infra red light from a light emitting diode is then applied through the cells and its intensity 
measured. This measurement was done twice - for 5 and 10 seconds, and then the mean for these 
values was calculated. 
Erythrocyte Deformability 
 
Erythrocyte deformability was measured with a Rheodyn SSD diffractometer (Bessis and 
Mohandas, 1975a; Bessis and Mohandas, 1975b; International Committee for Standardization in 
Haematology, 1986) at three different shear forces, 0.6, 6.0 and 30.0 Pa. The blood sample is added to 
a viscous solution of Dextran and placed in the instrument between one stationary disk and a rotating 
one. The rotation of the disk produces different well-defined shear forces dynamic viscosity (Pa.s), 
while a laser beam penetrates the solution and gives different diffraction patterns. The light intensity 
of these patterns is measured at two different points (A and B), equidistant from the center of the 
image and the erythrocyte elongation index (EEI) is obtained, in percentage, with the formula: 
 
   ( )  
   
   
     
 
Three different shear stress forces (0.6 Pa, 6.0 Pa and 30.0 Pa) were compared when studying 
erythrocyte deformability. Dextran, the reagent used in the erythrocyte deformability test, is a neutral 
 
macromolecule that allows to see the formation of rouleaux when RBC are resuspended in electrolyte 
solutions (Bäumler et al., 1999). 
Measuring the NO in erythrocytes 
 
NO was measured with a Nitric Oxide Measuring System. The blood was centrifuged for 10 
minutes and plasma was removed. A sodium chloride 0.9% at pH 7.0 solution was added to 1.5 μl of 
erythrocyte suspension in order to reach an Ht of 0.05%. A magnet was then put in the solution. The 
amino-IV sensor (Carvalho et al., 2004), linked to a computer and to the NO measuring system, was 
submerged in the solution and Ach 10
-3
 M was added. The value for NO was calculated using the 
peaks that the measuring system gives when adding the Ach, as this alteration is proportional to the 
amount of NO mobilized by Ach-stimulated erythrocyte. 
Measuring the S-nitrosoglutathione (GSNO) concentration in erythrocytes 
 
GSNO concentration was calculated using the values obtained with the Thermo Spectronic 
Genesys 10UV-VIS Spectrophotometer (Guevara et al., 1998). The blood was centrifuged at 11000 
rpm and plasma was removed. Mill-Q water, ethanol and chloroform were added to the erythrocyte 
suspension and it was vortexed. The measurement was based on the Griess Reaction using a 
commercial available kit by Invitrogen. Briefly, a solution was made containing components A and B 
of Griess reagent kit and PBS pH 7.4 solution. Erythrocyte suspension and Mill-Q water were added 
to this solution. Then, HgCl2 was added to this mixture in one cuvette but not in the other in order to 
compare. Two different controls were used: one with the Griess reagents plus PBS pH 7.4 solution and 
water, and the other with the same components plus HgCl2. The cuvettes were left to incubate in the 
dark for 20 minutes and then were read in the spectophotometer at 490 nm. 
 
2.3.3. – Statiscal Analysis 
Statistical analysis was performed using SPSS (Statistical Package for Social Sciences) program, 
version 2.7.0 and also R software (version 2.11.1).  
Values of p<0.05 were considered statistically significant. 
Distribution of the hemorheological markers between the various groups of patients was analyzed 
using the nonparametric Kruskal-Wallis test. This test does not assume that the data is normally 
distributed, but it is based on other assumptions: data is independent from each other and is selected 
randomly from the population. 
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Furthermore, in order to compare the longitudinal variations of STEMI patients, blood markers 
were repeatedly measured in the same patient at two different time-points. Consequently, the 
observations are inter-correlated and common statistical methods as analysis of variance or non-
parametric correlations are unsuitable. For that reason, a regression algorithm that accounts the effect 
of repeated measures was applied. The chosen statistical method was the linear mixed effects (LME) 
that models the concentrations of blood markers through time considering that measures for each 
patient were not independent. This statistical model describes the longitudinal variations of each 
patient by calculating slopes and averages of the variables in each time point. Therefore, it allows to 
estimate the differences in average slopes between hospital admission (day 0) and day 30, giving a 
measure of the variation of each blood marker over time. 
 
2.4. – Results   
2.4.1. – Characterization of the Study Groups 
The clinical characteristics of the patients allocated in the STEMI and in the RA study groups are 
listed in Table 2.1. Baseline clinical and demographical data were registered for each of the patients at 
the hospital: age, sex, weight, height, smoking habits, blood pressure, hyperlipidemia, hypertension, 
diabetes mellitus and abdominal fat.  
Waist perimeter, systolic blood pressure, diastolic blood pressure and abdominal fat were 
measured for all the RA patients. Unfortunately, the baseline clinical data is not available for the 
control group due to the type of agreement established with Instituto Português do Sangue.  
Blood test results that included blood cell count and CRP levels were also registered. In the 
STEMI group there is additional information about the culprit lesion regarding stenosis, the type, 
location and number of vessels approached and stents used. 
All the STEMI patients were taking at least one kind of medication. Six STEMI patients (40%) 
had multivessel disease. In seven patients the culprit vessel was the right coronary artery, in six 
patients it was the left descending coronary artery, and in one it was the circumflex artery. Six patients 
were lost in the follow up. 
  
 
Table 2.1 - Baseline clinical characteristics of the subjects enrolled. ACE – angiotensin-converting-enzyme; 
BMI – body mass index; BMS - bare-metal stent; DES - drug-eluting stent; LAD - left anterior descending 
coronary artery; LCX - left circumflex artery; RCA - right coronary artery. 
Values expressed as mean±sd, except when otherwise indicated. 
 
  
 CTR 
(n=15) 
RA 
(n=25) 
STEMI 
(n=15) 
Sex (f/m) 4/11 19/6 5/10 
Age (y) - 60±13 64±12 
BMI (kg/m
2
) - 26±3 28±3 
Waist perimeter (cm) - 84±8 - 
Systolic BP (mm Hg) - 135±16 - 
Diastolic BP (mm Hg) - 80±8 - 
Risk factors 
Smoking (n (%)) - 3 (12) 4 (27) 
Hyperlipidemia (n (%)) - 16 (64) 8 (53) 
Hypertension (n (%)) - 14 (56) 13 (87) 
Diabetes (n (%)) - 3 (12) 4 (27) 
Abdominal fat (n (%)) - 4 (16) - 
Pre-event medication 
   Aspirin (n (%)) - - 11 (73) 
   ACE-inhibitor (n (%)) - - 6 (40) 
   β-blockers (n (%)) - - 11 (73) 
   Statins  (n (%)) - - 12 (80) 
Angiographic data 
   Stenosis (%) - - 99 
   TIMI Class 
       Normal flux (TIMI = 3) (n (%)) - - 2 (13) 
       Occlusion (TMI <2) (n (%)) - - 12 (80) 
   Multivesell disease (n (%)) - - 6 (40) 
   Culprit vessel 
       LAD (n (%)) - - 6 (40) 
       RCA (n (%)) - - 7 (47) 
       LCX (n (%)) - - 1 (7) 
   Number of stents 
       1 stent (n (%)) - - 5 (33) 
       2 stents (n (%)) - - 6 (40) 
       3 stents (n (%)) - - 1 (7) 
       4 stents (n (%)) - - 1 (7) 
   Stents type 
       BMS (n (%)) - - 7 (47) 
       DES (n (%)) - - 6 (40) 
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2.4.2. – Hemorheological Markers 
Concerning the values of hemorheological and biochemical parameters obtained for the three 
study groups (Table A.1 in the appendix), it is possible to observe that STEMI at day 0 and RA 
patients did not significantly differ from the deformability values obtained in the control group (Fig 
2.1). 
 
 
Figure 2.1 - Variations of erythrocyte deformability, at 0.6 Pa, 6.0 Pa and 30.0 Pa, between the control, RA and 
STEMI (day 0) groups. 
 
After performing the statistical analysis for the erythrocyte aggregation markers, a significant 
difference was only observed in the values of erythrocyte aggregation at 10s between STEMI patients 
at hospital admission and healthy volunteers. No significant difference was obtained when comparing 
the RA group to the control group (Fig. 2.2). 
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Figure 2.2 - Variations of erythrocyte aggregation at 5 s and 10 s between the control, RA and STEMI (day 0) 
groups. 
 
Concerning the erythrocyte NO and GSNO concentrations, no differences were verified between 
STEMI patients at hospital admission, RA patients or controls (Fig. 2.3). 
 
 
Figure 2.3 - Variations of erythrocyte NO and GSNO concentrations between the control, RA and STEMI (day 
0) groups. 
 
2.4.3. – Longitudinal Variations in STEMI Group 
In STEMI patients, the longitudinal variations in the hemorheological markers were inspected 
using special statistical models. The linear mixed effect (LME) model was the chosen one to model 
each variable as a response variable over time.  
The longitudinal variations in STEMI patients for erythrocyte deformability were non significant 
(F>0.21, p>0.66; Fig. 2.4), and the same happens for erythrocyte aggregation (F>1.06, p>0.27; Fig. 
2.4). 
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Figure 2.4 – Longitudinal variations of erythrocyte deformability (at 0.6 Pa, 6.0 Pa and 30.0 Pa) and aggregation 
(at 5s and 10s) of STEMI patients at hospital admission and 30 days after. 
 
LME statistical analysis shows that there are also no changes over time in the concentrations of 
NO (F=0.03, p=0.87; Fig. 2.5) and GSNO (F=1.03, p=0.35; Fig. 2.5) in erythrocytes of STEMI 
patients. 
 
 
Figure 2.5 – Longitudinal variations of concentration of NO and GSNO in erythrocyte of STEMI patients at 
hospital admission and 30 days after. 
 
Furthermore, the difference between the STEMI patients at day 30 and RA and control groups 
were also verified. Once again no variations were observed between RA and controls and STEMI 
group at day 30 (Table A.1 in the appendix). 
 
 
0
10
20
30
40
50
60
0 30
E
ry
th
ro
c
y
te
 d
e
fo
rm
a
b
il
it
y
 (
%
)
Time (days)
0.6 Pa
6.0 Pa
30.0 Pa
0
2
4
6
8
10
12
14
16
18
20
0 30
E
ry
th
ro
c
y
te
 a
g
g
re
g
a
ti
o
n
 (
s
)
Time (days)
5 s
10 s
0,0
1,0
2,0
3,0
4,0
5,0
0 30
E
ry
th
ro
c
y
te
 N
O
 (
n
M
)
Time (days)
0,0
1,0
2,0
3,0
4,0
5,0
0 30
E
ry
th
ro
c
y
te
 G
S
N
O
 (

M
)
Time (days)
 
2.5. – Discussion 
Resulting from an atherosclerotic plaque rupture, STEMI is a condition responsible for a very high 
percentage of deaths around the world every year. After plaque rupture, the highly thrombogenic 
plaque content is exposed to the blood in the arterial lumen and the coagulation cascade is initiated 
(Davies, 2000), which leads to an acute inflammatory reaction. Thrombosis causes a critical reduction 
in the blood flow that is severely below the myocardium’s need. When perfusion stays in these 
alarming levels for long enough, oxygen and nutrients supply to cardiac muscle is interrupted 
(ischemia) and partial necrosis of the muscle occurs (Collinson and Gaze, 2007). 
Erythrocyte deformability is one of the most important properties of erythrocytes and plays a 
crucial role on the way they behave. Along with erythrocyte aggregation, it is one of the determinant 
factors for blood viscosity (Silva, 1982). Studies have shown a relation between cardiovascular 
diseases and alterations of deformability, suggesting that erythrocyte deformability index (EDI) may 
be potentially used as a predictor in coronary diseases (Qin et al., 1998). Decreased RBC 
deformability is associated with high variations in red cell distribution width (RDW) – in RBC 
volumes – which in turn is associated with increased risk for cardiovascular diseases through 
impairment of blood flow in the microcirculation (Patel et al., 2013). Autocrine function of vascular 
endothelium has a very important role regulating the RBC rheology in the blood flow (Martin, 2012). 
When taking into account the pathophysiology of STEMI (e.g., decrease in the blood flow and the 
existence of ischemia and possible necrosis) and the data from previous studies (Qin et al., 1998; Patel 
et al., 2013) that show a correlation between erythrocyte deformability and cardiovascular diseases, a 
significant difference in the values of these markers was expected when comparing STEMI with the 
control group. However, in the present study no significant difference was observed between STEMI 
patients and healthy donors. 
Erythrocyte aggregation is one of the determinant factors of blood viscosity. High values of 
plasma viscosity and an increase of erythrocyte aggregation tendency has been observed in patients 
with ischemic heart diseases (Kesmarky et al., 1998). Erythrocyte aggregation is influenced both by 
extrinsic factors - levels of plasma protein, hematocrit, and shear rate - and intrinsic factors, such as 
RBC shape and membrane surface charge (Saldanha et al., 2012).  
Erythrocytes tend to aggregate more under conditions of low shear stress rates, even though the 
attractive forces are relatively weak. As the shear stress increases, the aggregates diminish in size and 
the RBCs align with the flow. 
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Aggregation was determined in stasis of the blood sample for 5 and 10 seconds. In this study we 
verified that STEMI patients at hospital admission presented lower erythrocyte aggregation than 
controls for the 10 second measurement. 
Since thrombosis causes a diminished shear stress in the blood flow of its site, a higher erythrocyte 
aggregation was expected. It has been observed in atherosclerosis and other vascular diseases that 
oxidative processes overcome RBCs defences, which makes these oxidative-modified RBCs act at 
periphery as pro-oxidant bullets that can modify behaviour and fate of other vascular tissues (Minetti 
et al., 2007). Perhaps the erythrocytes became oxidative-modified in such a degree that their 
aggregation lowered. Another explanation is the existence of some agent – possibly some medication 
taken by the patient – that has this effect on aggregation.  
One could hypothesize that the inexistence of differences between groups for the erythrocyte 
aggregation at 5s may be due to the fact that erythrocytes need a longer time to aggregate. Kayar et al. 
(Meiselman et al., 2007) performed experiments on the effects of ischemia and reperfusion in rats and 
observed that erythrocyte aggregation was not affected by 10 minutes of ischemia, but was 
significantly reduced after 15 minutes of reperfusion, equally in plasma and in dextran medium. 
One of the causes for the lack of significant differences between the control and STEMI groups 
regarding erythrocyte deformability and aggregation may be related with the medication intake of 
STEMI patients. 
After having an STEMI episode, the patient is treated with medication that includes aspirin, β-
blockers, ACE-inhibitors, statins and platelet inhibitor agents. β-blockers are used as secondary 
prevention and intent to reduce cells stress response, aspirin prevents platelet aggregation and 
vasoconstriction, ACE-inhibitors lower blood pressure by dilatating blood vessels and statins lower 
the cholesterol level. All these drugs aim to revert the situation caused by atherosclerosis, so there are 
no more acute demonstrations of the cardiovascular disease. A month after suffering from STEMI the 
patient should present stabilized and normal levels of blood markers. Indeed, no significative 
differences between the markers of the STEMI follow up group and the control group were obtained, 
which corresponds to the expected results. 
It has been demonstrated in several studies that aspirin has an effect in platelet function, but some 
results also lead to the idea that aspirin may have a direct effect on erythrocytes as well. Bouhmadi et 
al. (2000) showed that erythrocyte aggregation is increased when oral contraceptives are being taken, 
and that 100 mg aspirin can reverse this hyper aggregation. Before this, Yousif (1999) hypothesized 
the possible rheologically active role of aspirin on erythrocytes through the acetylation of intracellular 
proteins and saturation of the cell interior with the osmotically active drug. Other studies concluded 
that in patients presenting acute coronary syndromes the antiaggregant effect of aspirin is modulated 
 
not only by platelets, but also by erythrocyte deformability and white blood cells count (Mannini et 
al., 2006). It is also shown that aspirin exerts a clear effect on the energy of adhesion between 
erythrocytes (Elblbesy et al., 2012). This finding needs to be studied further in order to understand the 
precise role that it plays in erythrocyte aggregation and deformability. 
NO is a gaseous signalling molecule derived from the endothelium with a direct role in 
pathogenesis of inflammation. It is a very reactive molecule with a wide spectrum of effects, 
depending on the concentrations of NO and the surrounding environment (Korhonen et al., 2005). 
Under normal physiological conditions NO gives an anti-inflammatory effect. It has been observed 
that NO augments production of the nuclear factor kappa B (NF-kB) inhibitor – a transcription factor 
involved in expression of genes encoding many pro-inflammatory functions of vascular wall cells and 
infiltrating leukocytes (De Caterina et al., 1995; Thurberg and Collins, 1998). Nitric oxide induces 
vasodilatation in intact endothelium that leads to an increase in blood flow, and it also is a potent 
neurotransmitter at neuron synapses and contributes to regulation of apoptosis (Sharma et al., 2007). 
Winlaw et al. (1994) reported increased levels of plasma nitrate, the stable end-product of NO 
production, in patients with heart failure. 
Being a signalling molecule, NO is equally responsible for some undesired effects. NO plays an 
important role in the regulatory functions in inflammation, such as: regulation of signalling cascades, 
transcription factors, vascular responses and cytokine production, proliferation and apoptosis 
(Korhonen et al., 2005). It reacts with superoxide anion and forms peroxynitrite (ONOO
-
), a potent 
oxidant that promotes vascular injury. 
Endothelial dysfunction leads to a reduced production of endothelium-derived NO and therefore 
its normal processes like dilatation of blood vessels, reduction of platelet and monocyte stickiness 
undergo disturbance (Scher, 2013). Considering all the physiological and hemorheological changes 
that occur during STEMI – starting with endothelial dysfunction - and all the cellular mechanisms in 
which NO takes part and plays an important role, a difference of erythrocyte nitric oxide values was 
expected to be observed. None of the groups, though, showed difference in their erythrocyte NO 
levels. 
Erythrocyte NO is produced by nitric oxide synthase (NOS) and reacts with intra-erythrocytic 
hemoglobin, which is directly linked to NO bioavailability and homeostatic vascular function 
modulation (Azarov et al., 2005). It regulates RBC deformability, favouring their passage through 
capillaries and stimulating blood flow in microcirculation (Eligini et al., 2013).  
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Given the relation between erythrocyte NO and their deformability (Carvalho et al, 2006), the fact 
that there was no difference between the deformability markers among the groups makes this result 
plausible.  
GSNO, a low molecular weight endogenous S-nitrosothiol, is a source of bioavailable NO and 
plays a critical role in its signalling. S-nitrosylation of proteins is linked to critical aspects in 
cardiovascular biology: S-nitrosylation of calcium cycling and essential regulators of β-adrenergic 
receptor signalling helps to maintain cardiac contractility (Hare, 2003; Ozawa et al., 2008), while S-
nitrosylation of hemoglobin regulates blood flow and oxygen delivery (Singel and Stamler, 2004). 
Results obtained from GSNO studies suggest that certain concentrations of it may modulate the 
remodelling/inhibition of fibrin networks - this relates to STEMI as changes in the architecture of 
fibrin networks is becoming increasingly recognized as another risk factor for cardiovascular diseases 
and thrombotic complications (Bateman et al., 2012). 
GSNO anti-inflammatory role has been demonstrated in several diseases. It attenuates infiltration 
of immune cells into the central nervous system, protects against demyelination and downregulates 
pro-inflammatory cytokines in multiple sclerosis models (Foster et al., 2009). 
Given the existing relation between NO and GSNO and the physiological changes that occur 
during STEMI, a significant difference of GSNO in the two groups was expected. It is to point out that 
no differences were observed in NO as well, which makes the results for GSNO less surprising. 
When comparing the results of the four studied hemorheological markers between the group of 
STEMI patients who just suffered from an acute myocardial infarction (the patients admitted in the 
hospital) and the same group but a month later (follow up), differences in the marker’s values are 
expected to be seen. Whereas the data from the first group is collected when the patient is undergoing 
severe thrombosis in coronary artery and the hemorheological and physiological properties of the 
surrounding tissues and blood are far from being normal, the data from the second is collected when 
the patient is stabilized and has returned to his daily chores and activities after being treated.  
After statistically analysing the data, it is concluded that no significative longitudinal variation 
differences exist between any of the studied hemorheological markers in STEMI patients.  
Even though theoretically a significant difference is expected between STEMI patients over time, 
the previous lack of significant difference between the STEMI admission and the control group, aside 
from the 10s sd erythrocyte aggregation, creates a propensity for the fact that there are no changes in 
the groups values. 
 
Rheumatoid arthritis (RA) is a chronic systemic inflammatory disease – there is a chronic 
activation of the innate immune system and a release of pro-inflammatory cytokines. It has been 
showed that patients suffering from RA are at greater risk of developing cardiovascular diseases (Van 
Doornum et al., 2002). Occurrence of CVD in RA patients has not been associated with traditional 
CVD risk factors like smoking, diabetes mellitus, hypertension, dyslipidemia and cholesterol 
(Warrington et al., 2005), which leads to the assumption that it is an independent risk for 
cardiovascular diseases.  
RA is correlated with accelerated atherosclerosis. Association of carotid intima-medial thickness 
(IMT) with inflammatory markers supports the evidence that CVD outcome in RA patients is indeed 
linked with inflammation (Arnab et al., 2013). The primary site of inflammation in RA is the synovial 
tissue – thin, loose vascular connective tissue that makes up the synovial membrane that surrounds 
joints. Cytokines such as TNF-α, IL-1β and IL-6 are released from this site of inflammation and act on 
distant tissues, causing insulin resistance, characteristic dyslipidemia, prothrombotic effects, pro-
oxidative stress and endothelial dysfunction (Sattar et al., 2003). 
Being such an active signalling molecule in inflammatory processes, NO is expected to present 
significantly different concentrations in patients suffering from RA as it is a disease in which constant 
inflammation occurs. Interestingly, Saldanha et al., (2011) conducted a study regarding RA patients 
and hemorheological parameters and concluded that erythrocyte NO production is independently 
associated with RA.  
The fact that dyslipidaemia presented in RA is pro-oxidative, and that cytokines can directly 
promote oxidative modification of LDL, suggest that there is a high level of oxidized lipids in RA 
(Sattar et al., 2003). Considering that oxidative stress reduces erythrocyte deformability, a significant 
difference in this marker for RA patients was expected. Although increased clotting potential with 
elevated levels of fibrinogen, fibrin D-dimer and von Willebrand factor is observed in RA patients 
(McEntegart et al., 2001), data from the present study shows no significant difference in erythrocyte 
aggregation and deformability, or in erythrocyte NO and GSNO. 
Among the molecules that can interact with the erythrocyte surface is hyaluronic acid (HA), which 
behaves similarly to albumin. A study has shown that HA causes significant concentration-dependent 
decrease in erythrocyte deformability and that it is the only plasma factor that significantly affects 
deformability (Luquita et al., 2010). In fact those authors found a correlation between erythrocyte 
rigidity index and HA concentration (Luquita et al., 2010). As RA patients present an elevated 
concentration of HA, that fact may partially explain the results obtain in the present work. 
A comparison between the RA and the STEMI admission was made.  
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RA and STEMI are both diseases in which inflammation plays an important role. They are linked 
because they share the common physiology of inflammation – pro-inflammatory cytokines, activated 
macrophages and other molecules. Therefore we can infer that the activity and levels of 
hemorheological markers is very similar in both cases, which is consistent with the data obtained from 
the comparison of both groups. No assumptions can be made, though, as both groups initially did not 
show any significant differences when compared with the control group. There is also the option that 
the two inflammation diseases have different intensities, which combined with the different etiology 
of both diseases would result in different values for these markers, which is not seen in these statistical 
results. Once again, an influence of medication could be hypothesized, however the number of patients 
included in the study did not allow that kind of statistical analysis of the data. 
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3. – Longitudinal evaluation of hemorheological markers in 
patients with sepsis 
 
3.1. – Sepsis in Today’s World 
Sepsis causes the death of thousands of people every year. It is a serious life-threatening disease 
with high rates of mortality that starts with a simple infection and can very easily escalate to death. 
Even though the percentage of survivors has been increasing in the past years, the number of people 
suffering from it has been increasing as well, which makes the mortality rates stay high. It is a true 
challenge for patients and physicians, and there is still a lot to be learned and many questions to be 
answered in clinical research. The need for awareness, precise diagnosis and effective treatment is 
essential. 
 
3.2. – Objectives 
The aim of this chapter is to unveil the contribution of hemorheological parameters for the sepsis 
pathophysiology, its evolution, and more importantly the outcomes. To achieve the proposed 
objective, four hemorheological markers – erythrocyte deformability, erythrocyte aggregation, NO and 
GSNO  erythrocyte concentrations – were measured in patients in different classes of sepsis upon their 
hospital admission, 24h, 72h after and at UCI discharge. Furthermore, the results were compared with 
subjects without inflammation, the control group.  
 
3.3. – Materials & Methods 
3.3.1. – Study Groups 
Sepsis Study Group: is composed by 14 patients with sepsis diagnosis at the Intensive Care Unit 
(ICU) of Hospital Beatriz Ângelo admission, of which 5 are females and 9 males. Blood samples were 
taken from patients suffering from sepsis at 4 different times during their hospitalization in the ICU of 
Hospital Beatriz Ângelo: the first blood collection was taken at time of the admission, the second was 
taken 24 hours later, the third was taken 72 hours later and the fourth was taken when the patient was 
discharged from the ICU. Some patients were lost to follow-up because they died or were discharged 
 
earlier from the ICU. In the present study were included patients in three different classes of sepsis 
(namely, systemic inflammatory response syndrome (SIRS), severe sepsis and septic shock). 
Control Group: Composed by 15 healthy volunteers (4 females and 11 males). Inclusion criteria 
for reference controls was absence of any history of coronary disease, dyslipidaemia or hypertension, 
any conditions limiting mobility, life threatening diseases, or any other disease or condition that would 
impair compliance and negative stress tests. Healthy volunteers were selected among the blood donors 
of the Banco Público de Sangue do Instituto Português do Sangue (Lisbon) under an institutional 
agreement with Instituto de Bioquímica da Faculdade de Medicina da Universidade de Lisboa. All 
donors were informed and signed a written consent. 
The blood samples (9 ml) were taken from January 2013 to June 2013. The blood was collected in 
heparin tubes and tested within the next 3 hours. 
The medical team of the Hospital Beatriz Ângelo provided all clinical data. 
 
3.3.2. – Methods  
The methods and reagents used to assess the erythrocytes aggregation and deformability, as well 
as the concentrations of NO and GSNO in erythrocytes were previously described in Section 2.3.2.  
 
3.3.3. – Statistical Analysis 
Statistical analysis was performed using SPSS (Statistical Package for Social Sciences) program, 
version 2.7.0 and also R software (version 2.11.1). 
Values of p<0.05 were considered statistically significant. 
Tests used to compare medians and distributions of the hemorheological markers were previously 
described in Chapter 2.3.3. The results of the statistical analysis performed to the data of the control 
group also are shown in Chapter 2.3.3. 
Furthermore, as described in Chapter 2, a LME analysis was made, allowing to estimate the 
differences in average slopes between UCI admission (0 hours) and the other time points (24 hours, 72 
hours and UCI discharge), giving a measure of the variation of each blood marker over time. 
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3.4. – Results 
3.4.1. – Characterization of the Study Groups 
The clinical characteristics of the sepsis study group’s patients are listed in Table 3.1. Baseline 
clinical and demographical data was registered for each of the patients at the hospital: age, sex, 
weight, height, temperature, mean arterial pressure and heart rate. Blood test results were also 
registered.  
Table 3.1 - Baseline clinical characteristics of the subjects enrolled. BMI – body mass index; HR – 
heart rate; MAP – mean arterial pressure; TMP – temperature. 
 
 
 CTR 
(n=15) 
SP 
(n=14) 
Sex (f/m) 4/11 5/9 
Age (y) - 66±14 
BMI (kg/m
2
) - 23±4.2 
TMP (
o
C) - 37±0.8 
MAP (mm Hg) - 75±18 
HR (bpm) - 101±22 
Death (f/m) - 0/4 
 
Medication  
Norepinephrine (n (%)) - 14 (100) 
Dopamine (n (%)) - 14 (100) 
Dobutamine (n (%)) - 14 (100) 
Epinephrine (n (%)) - 14 (100) 
Values expressed as mean±sd, except otherwise indicated. 
 
 
All patients were administered medication during the treatment. Seven patients were diagnosed 
with septic shock, three with severe sepsis and four with sepsis. Four patients died, three during their 
internment in the ICU and one after being discharged. 
Unfortunately, the clinical baseline data is not available for the control group due to the type of 
agreement established with Instituto Português do Sangue. 
 
3.4.2. – Hemorheological Markers 
When looking at the values of hemorheological and biochemical parameters obtained for patients 
with sepsis at UCI admission (Table A.2 in the appendix) and comparing them with the control group, 
 
we can see that values for erythrocyte deformability at all shear stress forces (0.6 Pa, 6.0 Pa and 30.0 
Pa) are higher in the sepsis group (Fig. 3.1).  
 
 
Figure 3.1 - Variations of erythrocyte deformability, at 0.6 Pa, 6.0 Pa and 30.0 Pa, between the groups of sepsis 
patients at UCI admission and of controls. 
 
Concerning the values of erythrocyte aggregation, the values for 5s aggregation are slightly higher 
in patients with sepsis at UCI admission (Fig. 3.2). For the 10s aggregation, no significant difference 
was obtained between both groups. 
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Figure 3.2 - Variations of erythrocyte aggregation, at 5 s and 10 s, between the groups of sepsis patients at UCI 
admission and of controls. 
 
No significant difference was obtained for the NO and the GSNO values when comparing control 
group with sepsis admission (Fig. 3.3).  
 
Figure 3.3 - Variations of NO and GSNO concentrations between the groups of sepsis patients at UCI admission 
and of controls. 
 
3.4.3. – Longitudinal Variations in Sepsis Group 
When looking at values of the hemorheological markers between sepsis patients at all the 4 time-
points (Table A.2 in appendix) it is possible to verify that the erythrocyte deformability did not change 
over time at any shear stress rate (F>0.48, p>0.71; Fig. 3.4). However, some differences exist 
compared to the control values. In fact, after 24 hours the values of deformability for 6.0 Pa and 30.0 
Pa are significantly higher than in healthy volunteers (p=0.003 and p=0.003, respectively). At 72 hours 
after UCI admission, sepsis patients present higher values of deformability, at all shear rates, than 
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controls (p=0.015, p=0.001 and p=0.001 for 0.6 Pa, 6.0 Pa and 30.0 Pa, respectively). At UCI 
discharge, differences were only found for 30.0 Pa (p=0.033). 
The longitudinal variations in sepsis patients for erythrocyte aggregation were also non significant 
(F>0.65, p>0.34). The levels of erythrocyte aggregation for 5 s significantly differ from those of 
controls in patients with sepsis at 72 hours (p=0.045) and at UCI discharge (p=0.033). 
 
Figure 3.4 – Longitudinal variations of erythrocyte deformability (at 0.6 Pa, 6.0 Pa and 30.0 Pa) and aggregation 
(at 5s and 10s) in sepsis patients at four time-points. 
Although the concentrations of NO in erythrocytes do not change over time (F=0.64, p=0.60; Fig. 
3.5), the concentrations of erythrocyte GSNO do (F=3.27, p=0.036; Fig. 3.5). The concentrations of 
GSNO decrease significantly until 72 hours (p=0.049), reaching values lower than controls (p=0.015). 
 
Figure 3.5 – Longitudinal variations of concentrations of NO and GSNO in erythrocyte deformability of sepsis 
patients at four time-points. 
 
3.4.4. – Hemorheological Markers Association to Prognosis of Sepsis Group 
Of the 14 patients that were enrolled in the ICU presenting sepsis, 4 died while being treated at the 
UCI. 
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When comparing the values between the two groups of sepsis patients it is possible to observe 
higher levels of 0.6 Pa erythrocyte deformability in non-survivor patients (Table A.3 in Appendix). On 
the other hand, 6.0 Pa and 30.0 Pa have higher values for the survivors group, except at 72 hours (Fig. 
3.6). Both 5 s and 10 s aggregation have higher values for the survivors (Fig 3.6). 
 
Figure 3.6 – Longitudinal variations of erythrocyte deformability (at 0.6 Pa, 6.0 Pa and 30.0 Pa) and aggregation 
(at 5 s and 10 s) in sepsis patients that survived (full line) and those that were dead before UCI discharge (dash 
line). 
For the concentrations of NO and GSNO in erythrocytes, non-survivors sepsis patients at 24 hours 
present higher levels than survivors do (Fig. 3.7). For erythrocyte GSNO concentrations, the levels of 
patients that did not survive did not change much over time, contrary to the survivors (Fig. 3.7).  
 
Figure 3.7 – Longitudinal variations of concentration of NO and GSNO in erythrocyte deformability of sepsis 
patients that survived (full line) and those that were dead before UCI discharge (dash line). 
No statistical analysis was performed because of the small size of the sample, especially in what 
concerns the number of patients with sepsis that did not survive until discharge. 
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3.5. – Discussion 
Sepsis is a very serious disease characterized by a systemic inflammatory response that starts with 
an infection. Our bodies release chemicals into the blood stream to fight the infection and this leads to 
an elevated inflammation. The number of people suffering from it has been increasing each year (Hall 
et al., 2011). 
Sepsis induces changes in microvascular properties related to vascular reactivity, leukocyte-
endothelial cell adhesion and vascular leakage. Microcirculatory derangements like loss of capillary 
density also develop. These losses are translated into loss of surface area for gas exchange, 
maldistribution of blood flow and increased heterogeneity in the flow, which leads to disturbances in 
tissue oxygenation (Bateman et al., 2001). 
A decrease in erythrocyte deformability and an increase of erythrocyte aggregation have been 
observed in patients with sepsis (Bateman et al., 2001; Baskurt et al., 1998). Erythrocyte dysfunction, 
when induced by infection, has an important role in the behaviour of the immune response and can 
contribute to organ dysfunction in patients with sepsis (Hall et al., 2011). 
A previous study has shown an elevated band-3 tyrosine phosphorylation in circulating RBC in 
sepsis patients (Condon et al., 2007). Band-3 is an erythrocyte membrane protein that affects directly 
cell shape, structure, function, flexibility and regulation of glucose metabolism, ion transport and cell 
lifespan (Zhang et al., 2000). Changes in the proteins normal state originate changes in these features. 
Alterations of the band-3 may be linked to RBC dysfunction (Condon et al., 2007). Rheological 
alterations that RBC suffer upon inflammation may contribute to blood congestion and impair oxygen 
exchange under septic conditions.  
A study indicates that an erythrocyte subpopulation, consisting of 20% of circulating erythrocytes, 
shows a pronounced decrease in deformability when compared to the other cells (Condon et al., 2003). 
This result indicates the possibility that only a portion of the RBC undergoes critical hemorheological 
changes that alter their deformability. More even, this study also demonstrates that decrease in 
erythrocyte deformability occurs in different degrees in a specific subpopulation. 
Erythrocyte deformability was measured at three different shear forces: 0.6 Pa, 6.0 Pa and 30.0 Pa. 
Whole blood samples were taken from sepsis patients at four different times during their internment. 
Data obtained from the comparison between patients with sepsis at ICU admission and the control 
group showed that there really is a significant difference among the two groups for the three 
deformability parameters. These results match the theory that inflammation causes a disturbance in the 
hemorheological properties of erythrocytes - which become more rigid - and therefore causes change 
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in their deformability. Rigidified erythrocytes are a constant presence in blood circulation in sepsis, 
maybe because their amount is so high that mononuclear phagocytes don’t have the capacity to 
phagocyte them (Powell et al., 1993).  
Interestingly, in sepsis patients, 24 hours after interment there are still significant differences 
among the deformability compared to the control group. The fact that sepsis is based on an acute 
inflammation spread out through the body that is very hard to fight and stop may explain why after 24 
hours of treatment and monitorization there are still differences in erythrocyte deformability. Even 
after 72 hours of being admitted in the ICU the patient presents significant differences in deformability 
values. The fact that after so many hours deformability continues far from its normal values leads to 
the idea that even with medication and treatment the erythrocyte hemorheological parameters are still 
disturbed and inflammation is still happening in the body. 
Even more surprising are the results of the comparison between the discharge and the control 
group, where significant differences are obtained once more for all the deformability measurements. 
Since the patients are being discharged from the ICU, deformability values were expected to be more 
similar to those from the control group. The fact that patients are being discharged from the ICU only 
means that they are no longer in a life-threatening situation, but inflammation may still be present in a 
lower intensity than at the acute phase. 
No significant differences among the markers of erythrocyte deformability were observed when 
comparing patients at ICU admission and 24 hours after, which can reinforce the idea that 24 hours is 
a little window of time to make an inflammatory disease like sepsis regress. No differences were 
observed between the sepsis patients at ICU admission and 72 hours or at ICU discharge. Therefore, 
the difference among these time-points along with the initial assumption reinforces the results 
obtained from the comparisons with the control group.  
Paradoxically, the three deformability measurements are the only markers whose differences are 
significant when evaluating the longitudinal variations of patients with sepsis. These results give the 
idea that sepsis patient’s markers change over time, besides presenting different values from those of 
healthy patients. Considering that these patients were interned in the hospital and then discharged, 
these differences may translate the progression of the treatment – inflammation is being suppressed 
and therefore erythrocyte deformability undergoes changes. 
An increase in erythrocyte aggregation is observed in sepsis. Aggregation is a complex 
mechanism, dependent of the surrounding medium composition and cellular factors such as the RBC 
membrane negative surface charge. Increased erythrocyte segmentation rate (ESR) is used as a criteria 
in diagnosis of sepsis. Elevated erythrocyte aggregation is the primary factor responsible for this 
increase in ESR, therefore it is directly linked to the sepsis condition. Increased erythrocyte 
 
aggregation may be related to tissue perfusion problems. Aggregation appears to be affected mostly by 
plasma factors (Baskurt et al., 1997). 
Erythrocyte aggregation was measured in two elapsed times: during 5 seconds and 10 seconds 
after stopping the applied speed of 600s
-1
 during 10sec
-1
. A significant difference was obtained for the 
5s measurement when comparing sepsis patients (at all time-points) with the control group, which 
correlates with the fact that erythrocyte aggregation is altered during sepsis.  
RBC aggregates tend to form in low shear rates and may increase blood viscosity and reduce flow. 
With the low perfusion created RBCs damage may worsen and become more prominent (Baskurt et 
al., 1997). The results obtained show that erythrocytes aggregate significantly in a short time – the 5s 
measurement. Given this, a significant difference for the 10s measurement was also expected. The fact 
that the 10 second measurement has no difference shows that erythrocytes somehow disaggregated 
after the first measurement and therefore have the same values of the healthy population. It is a 
curious fact that may occur due to the damage that erythrocytes suffer and that alters their physiology 
and consequent behaviour. 
Oxidative damage to erythrocytes has been reported in sepsis patients and related to tissue 
ischemia and white blood cells. The damage is related to erythrocyte deformability and can indirectly 
affect their aggregation as impaired RBC deformability may decrease aggregation (Baskurt et al., 
1997). 
The fact that there is a difference in aggregation between the sepsis group and the control group 
throughout time is consistent with the information obtained regarding erythrocyte deformability. This 
plus the fact that there is no significative longitudinal variations contributes to the idea that 
inflammation persists in patients body all through the treatment and even by the time of the discharge 
from the ICU. 
Nitric oxide is a signalling molecule formed from L-arginine conversion by a family of 3 NOS 
enzymes. NO has a key role in the regulation of vascular tone and blood pressure. In normal 
conditions it works as a vasodilator. In sepsis, nitric oxide, along with superoxide anion and hydrogen 
peroxide, is released from activated phagocytes and may target erythrocytes causing a decrease in their 
deformability and membrane oxidation (Bateman et al., 2001). 
Inflammation causes an increase in levels of pro-inflammatory cytokines such as interferon-
gamma (IFN-γ), which in turn leads to production of NO. Inhibition of NO synthesis can promote the 
resolution of shock and temporarily improve hemodynamic variables (Wang et al., 2010). A high level 
of NO is a dangerous sign of septic shock (El-Sallab et al., 2002). 
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In the present study, the NO in erythrocytes did not change over time in patients with sepsis, nor 
was it different from healthy individuals. These results go against the initially expected. The role of 
NO in sepsis is wide and well known and previous results have determined a significant difference in 
NO levels between sepsis patients and other groups. The fact that NO has been reported to modulate 
RBC deformability added to the significant differences obtained for the three deformability markers, 
reinforced the hypothesis that this marker should have shown differences between the groups 
(Bateman et al., 2001). 
The fact that erythrocytes scavenge NO when oxygen tension is high and release it when it is low 
(as happens in sepsis) is another reason why a significant difference was expected in this marker. 
Cardiovascular abnormalities in severe sepsis are derived from the release of inflammatory 
mediators like NO and may contribute to shock. Studies have showed that excessive synthesis of 
inducible nitric oxide synthases (iNOS) leads to production of excessive NO and free radicals and 
results in hypotension and tissue injury in sepsis (Powell et al., 1993). One possible explanation may 
be the existence of a compensatory mechanism so that NO produced by iNOS does not increase, 
resulting this way in a protective action against further injury. 
Furthermore, it is known that alterations of NO derivatives inside the erythrocyte depend on both 
internal and external stimuli, like ACh (Saldanha et al., 2013). Therefore, the inexistence of 
differences among groups for erythrocyte NO may be explained by the fact of NO has undergone 
chemical reaction and is present in the erythrocyte as other molecule.  
Opposing the results from studies with a positive outcome when studying NO levels in sepsis, 
Terregino et al. (2000) did not find an increase of NO metabolites in sepsis patients. It is to note that 
in his study patients were presumed to have sepsis upon the arrival at the UCI and have not yet 
developed septic complications, which may have resulted in incorrect diagnosis. 
GSNO is an endogenous low-molecular-weight nitrosothiol formed in the extracellular milieu that 
plays a critical role in NO signalling (Gaston et al., 1993). Circulating erythrocytes contain S-
nitrosohemoglobin (SNO-Hb) that results from the reaction of GSNO and hemoglobin. Researchers 
found out that the combination of SNO-Hb with glutathione results in relaxation of vessels (Spencer et 
al., 2000). In vitro experiments showed that an NO exchange occurs between hemoglobin and GSNO 
(Romeo et al., 2003). Therefore, GSNO is the main chariot in which biologically active NO is 
transported in peripheral blood (Liu et al., 2004). 
The fact that the only the comparison between the control and the 72 hours sepsis groups had any 
significant difference between the erythrocyte GSNO values was not expected at all. If the erythrocyte 
GSNO change was time related then the discharge group should have shown a significant difference as 
 
well, as there had been even more time since the start of the treatment. The absence of difference may 
be due to GSNO leaving the cell, and therefore its quantification is not possible.  
GSNO originates with the reaction of NO with GSH, which is an abundant molecule in the 
erythrocyte (Saldanha et al., 2013). The lack of significative variance in GSNO levels may be because 
GSH was being formed in order to even the oxidative stress, or SNO-Hb, or even nitrates and nitrites. 
Given the relation of NO and GSNO, and the fact that none of the groups presented a change in 
their NO values, the fact that only one group showed a change in the GSNO values was not a complete 
surprise. The results for both these markers may be related to the fact that the sample was of a small 
size. 
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4. – Conclusions & Implications 
 
4.1. – Conclusions 
The group of inflammatory diseases is vast. They have different mechanisms and cellular targets 
but are united under one biological process that is common to all: inflammation. This work focused on 
three such diseases – rheumatoid arthritis, acute myocardial infarction, and sepsis. All three of them 
arise big health issues, change the lives of thousands of people, are present all around the globe, and 
make governments spend a very large amount of money in order to treat them. Many studies have 
already been done in order to uncover the maximum possible that there is to know about them, but 
there is still a big road ahead. Prevention, efficient diagnosis and treatment are all essential not only 
for the patients´ wellbeing but also so that the medical teams can do the best job possible when 
treating these patients.  
In this context, the identification of high-risk patients is of extreme importance. The present work 
aimed to study the relation of hemorheological parameters with acute inflammatory diseases. To 
achieve that four erythrocyte markers were analyzed – deformability (at 0.6 Pa, 6.0 Pa and 30.0 Pa) 
and aggregation (at 5s and 10s), NO and GSNO – in order to study their changes and behavior among 
the different groups of diseases. The fact that RBC features can be used as markers in diagnosis is a 
thought shared by many. The four markers used in this study can be strong candidates for this. 
Patients from the STEMI group had their blood taken at two points: upon the admission in the 
hospital (at infarction onset), and a month later. The values from these two harvests were compared 
among each other in a longitudinal study, but also with a healthy control group, as well as with 
samples from patients suffering from rheumatoid arthritis (chronic inflammatory disease).  
AMI patients at infarct onset present significant lower levels of erythrocyte aggregation (10s) 
compared to the controls, but no differences were observed for the other hemorheological markers. 
Furthermore, no longitudinal variations were verified for neither of the markers. Changes in 
erythrocyte aggregation, deformability, and NO have been previously observed in patients suffering 
from both diseases, however in the present study a possible effect of pre-event medication could 
influence the results. 
A longitudinal evaluation was also performed in sepsis: upon hospitalization in the ICU, 24 hours, 
72 hours later, and at the discharge. Changes in the erythrocyte deformability and aggregation (5s) 
were obtained compared to the controls. Although variations over time in sepsis patients were not 
observed for the majority of the studied parameters, the erythrocyte GSNO levels significantly 
 
decreased at 72 hrs. This time-point also marks the changes between survivors and non-survivors for 
the studied hemorheological parameters, pointing out the importance of hemorheology in sepsis. 
These results reinforce the relation between blood rheology and acute inflammation, as 
inflammatory processes have a direct action on erythrocytes properties, namely on the four markers 
that this study was based on. They also show that different conditions have different impacts on these 
markers, which can be related to the pathophysiology of the condition. 
 
4.2. – Study Limitations 
Obtaining the maximum number of blood samples in a short period of time was a difficulty that 
had to be overcome. It was a major concern as it is a sample based study, and thought the final work 
ended up with a decent amount of samples for a longitudinal study, it is still far from ideal in what 
concerns the statistical analysis. It takes a lot of coordination and commitment from the medical teams 
in order to retrieve blood from patients. The patients have to agree to donate the blood voluntarily, so 
it is also an obstacle as not everyone is willing to do so.  
 
4.3. – Implications and Future Research 
Changes in blood rheology (such as deformability and aggregation) have been observed in patients 
suffering from all three diseases (RA, STEMI and sepsis), so a further pursuit in the study of this topic 
is necessary. A bigger size sample is necessary in order to make the most accurate statistics possible. 
The group should ideally also contain the same sex ratio. 
Parallel analysis of nitrites, nitrates, and glutathione can give more information regarding the four 
markers studied, and also expand the knowledge of their interrelation. Parallel studies of the molecular 
mechanisms of the inflammation are crucial for the understanding of the core of this process, as well 
as to help complement the information obtained when studying the markers. 
More detailed clinical information of the patients will also improve the data obtained from every 
study as it can give a solid background to the researcher and help build a bigger picture of the 
pathophysiology of diseases. 
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Appendix A 
 
 
Table A.1 - Hemorheological and biochemical markers of the studied population of STEMI and AR patients and 
healthy volunteers. 
 
Control 
(n=15) 
RA 
(n=25) 
STEMI 
Day 0 
(n=15) 
Day 30 
(n=9) 
Age (y) - 60±13 64±12 - 
BMI (kg/m
2
) - 26±3 28±2.5 - 
Clinical Analysis 
Total Cholesterol (mg/dl) - - 160±47 - 
LDL-C (mg/dl) - - 109±40 - 
HDL-C (mg/dl) - - 38±7.7 - 
Triglycerides (mg/dl) - - 153±64 - 
Albumin (g/l) - - 42±3.2 - 
Glucose (mg/dl) - - 107±45 - 
Hgb (g/dl) - - 13±1.9 - 
Erythrocytes (x10^6/ul) - - 4.3±0.53 - 
Hematocrit (%) - - 40±5.5 - 
Leukocytes (x10^3/ul) - - 8±2.3 - 
CRP (mg/l) - - 8.4±11 - 
Troponin (ng/ml) - - 6.7±23 - 
BNP (pg/ml) - - 142±230 - 
Hemorheological parameters 
Deformability 0.6 Pa (%) 6±2.7 6±3 7±3.5 7±3.4 
Deformability 6.0 Pa (%) 40±4 41±4 41±6 40±2.5 
Deformability 30.0 Pa (%) 47±3 50±6 51±5.5 48±4.8 
Aggregation 5s (s) 13±2.5 11±3 11±5.5 13±4 
Aggregation 10s (s) 21±5 16±5.5 14±9.4 * 18±5.2 
NO (nM) 2.4±1.9 1.1±0.95 2.5±3.4 1.4±1.8 
GSNO (µM) 5.2±3.2 7.7±13 4.1±2.8 4.5±3.1 
Values expressed as mean±sd. * p<0.05 versus CTR. 
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Table A.2 - Hemorheological and biochemical markers of the studied population sepsis patients and healthy volunteers. 
 
Control 
(n=15) 
SEPSIS 
UCI Admission 
(n=14) 
24h 
(n=14) 
72h 
(n=11) 
UCI Discharge 
(n=4) 
Age (y) - 66±14 66±14 66±14 66±14 
BMI (kg/m
2
) - 22.8±4.2 - - - 
Baseline data 
TMP (
o
C) - 37±0.78 37±1.1 37±0.64 37±0.64 
MAP (mm Hg) - 75±18 83±14 93±22 94±12 
HR (bpm) - 101±22 94±23 98±134 73±4.2 
Clinical Analysis 
Hgb (g/dl) - 11714±6352 11771±5922 12156±6184 8250±7849 
Leukocytes (/ml) - 219214±208440 199286±174896 240667±214732 267500±195869 
Platelets (/ml) - 16±4.5 16±5.0 16±6.2 12 
Time Prothromb. (seg) - 32±19 32±28 23±20 22±30 
APTT (seg) - 563±112 646±219 483 488 
Fibrinogen Clauss (mg/dl) - 87±55 88±44 77±52 38±9.2 
Urea (mg/dl) - 2.2±2.2 1.9±1.4 1.6±1.8 3.9±5.1 
Serum Creatinine (mg/dl) - 28±33 53±83 19±10 - 
Hemorheological parameters 
Deformability 0.6 Pa (%) 6.1±2.7 9.9±5.1 * 10±4.3 10±3.5 * 9.9±4.5 
Deformability 6.0 Pa (%) 40±4.0 45±7.2* 45±6.8* 47±7.2 * 45±8.5 
Deformability 30.0 Pa (%) 47±2.8 57±6.7 * 56±6.0 * 59±4.9* 57±5.5 * 
Aggregation 5s (s) 13±2.5 14±5.2 * 16.5±6.2 17,5±3.1 * 17±2.1 * 
Aggregation 10s (s) 21±4.9 19±7.7 23±11 24±7.1 22±5.3 
NO (nM)  2.4±1.9 5.0±13 1.9±1.3 1.8±1.3 1.9±0.94 
GSNO (µM) 5.3±32 14±25 8.8±10  3.5±3.3 * 3.8 * 
Values expressed as mean±sd. * p<0.05 versus CTR. 
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Table A.3 – Longitudinal variations of hemorheological markers in sepsis patients according to the outcome at UCI discharge. 
 Survivors 
 
Dead 
Admission 24 h 72 h Discharge Admission 24 h 72 h Discharge 
Deformability 0.6 Pa (%) 9.6±5.8 9.6±4.3 9.6±3.9 9.4±5  9.8±3.8 112±5.5 13 - 
Deformability 6.0 Pa (%) 45±8.2 46±7.5 46±8.4 45±9.7  42±6.3 42±7.2 50 - 
Deformability 30.0 Pa (%) 58.1±6 58±5.2 58±5.1 57±6.1  50±7.7 55±7.7 61 - 
Aggregation 5s (s) 14±4.8 16±6.7 17±2.6 17±4.8  11±6.5 15±6.4 13 - 
Aggregation 10s (s) 19±6.9 22±11 24±7.4 23±5.8  15±8.2 18±11 19 - 
NO (nM) 1.5±1.6 1.5±1.1 1.4±1.0 1.7±1  1.6±0.6 2.5±1.2 1.4 - 
GSNO (µM) 20±32 10±12 19±42 4.9±3.0  8.2 5.5±3.8 0.57 - 
Values expressed as mean±sd 
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Appendix B – Materials and Reagents 
 
 
 List of the materials used in this study: 
 Beakers (Normax) 
 Cuvettes 1 ml, 3 ml 
 Microtubes 1.5 ml, 2 ml (Eppendorf) 
 Freezer at -80ºC 
 Micro-pipettes (Gilson) 
 Gloves  
 Biofuge 15 Centrifuge (Heraeus) 
 Magnet 
 Myrenne Aggregometer MA-1 (Myrenne GmbH) 
 Nitric Oxide Measuring System (Innovative Instruments, Inc.) 
 Pipette Tips 
 Refrigerator 
 Rheodyn SSD (Myrenne GmbH,) 
 TC Centrifuge (Sorvall) 
 Syringes 3 ml 
 Thermo Spectronic Genesys 10UV-VIS Spectrophotometer (Thermo Fisher Scientific) 
 Vibrofix VF1 Electronic Shaker (IKA-Werk) 
 Vacutainer blood collection tubes 
 
 List of the reagents used in this study: 
 Acetylcholine 10
-3
M (Sigma) 
  Chloroform (Sigma) 
 Dextean (Sigma) 
 Ethanol 95% 
 Griess Reagent (Invitrogen) 
 HgCl2 
 Milli-Q Water (Millipore) 
 NaCl 0,9% pH 7.0 
 
